Daniel Jorgensen joins PolyMedix
This article was originally published in Scrip
Executive Summary
PolyMedix, a biotech developing novel drugs for the treatment of acute cardiovascular disorders and serious infectious diseases, has appointed Dr Daniel Jorgensen senior vice-president of clinical development and chief medical officer. Dr Jorgensen previously held senior leadership roles in the global research and development division of Pfizer, leading the company's first vaccine development group.